Dialog Box


Combination treatment increases recurrent glioblastoma survival rate

                                                                   A graphic highlighting glioblastoma.               

A new clinical trial aimed at treating recurrent glioblastoma has been launched by a collaboration of American research institutions.

The trial, involving independent researchers and biopharmaceutical company ZIOPHARM Oncology, will experiment injecting the Ad-RTS-hil-12 gene directly into the patient’s tumour in conjunction with the veledimex drug, which activates the gene. This combination engages the patient’s immune system, producing a targeted anti-tumour response

Glioblastoma is the most aggressive type of brain cancer, affecting approximately 74,000 people across the globe annually. Despite patients undergoing rigorous treatments, survival of the cancer remains alarmingly low, with the average prognosis of just five to eight months following diagnosis.

ZIOPHARM Oncology recently announced positive data at the annual Society of Neuro-Oncology meeting. The researchers discovered an increased survival rate in patients with recurrent glioblastomas following their treatment with the gene therapy.

Dr Antonio Chiocca, the lead author of this presentation, also observed a decrease in the size of tumours in several patients.

“We’re excited to see increasing evidence of a targeted, local immune response making brain tumours hot and illustrating how this immunotherapy contributes to patients’ survival,” Dr Chiocca said.

Furthermore, ZIOPHARM Oncology initiated a trial to evaluate this gene therapy as a treatment for paediatric brain tumours. If successful, this treatment could have significant impact on patients, potentially improving survival rates and decreasing the harm caused by brain tumours. 

Help fund vital brain cancer research